A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct.
The intracellular bacterial pathogen Chlamydia trachomatis is a major cause of sexually transmitted disease worldwide. While protective immunity does appear to develop following natural chlamydial infection in humans, early vaccine trials using heat-killed C. trachomatis resulted in limited and transient protection with possible enhanced disease during follow-up. Thus, immunity following natural infection with live chlamydia may differ from immune responses induced by immunization with inactivated chlamydia. To study this differing immunology, we used murine bone marrow-derived dendritic cells (DC) to examine DC maturation and immune effector function induced by live and UV-irradiated C. trachomatis elementary bodies (live EBs and UV-EB, respectively). DC exposed to live EBs acquired a mature DC morphology; expressed high levels of major histocompatibility complex (MHC) class II, CD80, CD86, CD40, and ICAM-1; produced elevated amounts of interleukin-12 and tumor necrosis factor alpha; and were efficiently recognized by Chlamydia-specific CD4+ T cells. In contrast, UV-EB-pulsed DC expressed low levels of CD40 and CD86 but displayed high levels of MHC class II, ICAM-1, and CD80; secreted low levels of proinflammatory cytokines; and exhibited reduced recognition by Chlamydia-specific CD4+ T cells. Adoptive transfer of live EB-pulsed DC was more effective than that of UV-EB-pulsed DC at protecting mice against challenge with live C. trachomatis. The expression of DC maturation markers and immune protection induced by UV-EB could be significantly enhanced by costimulation of DC ex vivo with UV-EB and oligodeoxynucleotides containing cytosine phosphate guanosine; however, the level of protection was significantly less than that achieved by using DC pulsed ex vivo with viable EBs. Thus, exposure of DC to live EBs results in a mature DC phenotype which is able to promote protective immunity, while exposure to UV-EB generates a semimature DC phenotype with less protective potential. This result may explain in part the differences in protective immunity induced by natural infection and immunization with whole inactivated organisms and is relevant to rational chlamydia vaccine design strategies.
Rey-Ladino
Jose
J
University of British Columbia Centre for Disease Control, 655 West 12th Ave., Vancouver, BC V5Z 4R4, Canada. robert.brunham@bccdc.ca.
Koochesfahani
Kasra M
KM
Zaharik
Michelle L
ML
Shen
Caixia
C
Brunham
Robert C
RC
D019264:Adoptive Transfer; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D001854:Bone Marrow Cells; D002454:Cell Differentiation / Q000276:immunology*; D002690:Chlamydia Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D002692:Chlamydia trachomatis / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity / Q000528:radiation effects; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010641:Phenotype; D018410:Pneumonia, Bacterial / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D014466:Ultraviolet Rays; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D001428:Bacterial Vaccines; D000949:Histocompatibility Antigens Class II; D015164:Vaccines, Inactivated; D018799:Intercellular Adhesion Molecule-1
J Immunol. 2000 Apr 15;164(8):4212-9
10754317
J Immunol. 1998 Aug 1;161(3):1439-46
9686609
J Infect Dis. 2000 Jun;181 Suppl 3:S538-43
10839755
Mol Med. 2000 Jul;6(7):604-12
10997341
Curr Top Microbiol Immunol. 2000;251:167-71
11036772
Infect Immun. 2000 Dec;68(12):6979-87
11083822
J Exp Med. 2001 Jan 15;193(2):233-8
11208863
Infect Immun. 2001 Jul;69(7):4667-72
11402013
Cell. 2001 Aug 10;106(3):259-62
11509173
J Immunol. 2001 Sep 15;167(6):3316-23
11544320
Infect Immun. 2002 Mar;70(3):1097-105
11854188
Eur J Immunol. 2002 Mar;32(3):742-51
11870618
BioDrugs. 2002;16(1):19-35
11908999
Infect Immun. 2002 Jun;70(6):2741-51
12010958
J Immunol. 2002 Jun 1;168(11):5589-95
12023355
Infect Immun. 2002 Jul;70(7):3793-803
12065523
J Clin Invest. 2002 Jun;109(12):1519-26
12070296
J Exp Med. 2002 Jun 17;195(12):1565-73
12070284
Trends Immunol. 2002 Sep;23(9):445-9
12200066
Cancer Res. 2002 Sep 15;62(18):5260-6
12234994
J Immunol. 2002 Dec 1;169(11):6324-31
12444139
Infect Immun. 2003 Jan;71(1):117-25
12496156
Nat Rev Immunol. 2003 Feb;3(2):133-46
12563297
Annu Rev Immunol. 2003;21:685-711
12615891
Mol Microbiol. 2003 May;48(3):671-83
12694613
Immunity. 2003 Jun;18(6):813-23
12818162
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8478-83
12815105
Cell Microbiol. 2003 Aug;5(8):493-500
12864809
Nat Rev Immunol. 2004 Jan;4(1):24-34
14704765
J Immunol. 2004 Feb 1;172(3):1727-34
14734755
J Immunol. 2004 Feb 15;172(4):2407-15
14764711
Am J Ophthalmol. 1979 Mar;87(3):350-3
434096
J Exp Med. 1985 Mar 1;161(3):526-46
3871837
Rev Infect Dis. 1985 Nov-Dec;7(6):717-25
4070905
Am J Trop Med Hyg. 1990 Apr;42(4):358-64
2331044
J Exp Med. 1990 Aug 1;172(2):631-40
2373994
J Exp Med. 1998 Sep 7;188(5):809-18
9730883
Nat Med. 1998 Dec;4(12):1409-15
9846579
Infect Immun. 1999 Apr;67(4):1763-9
10085016
Sex Transm Dis. 1978 Apr-Jun;5(2):73-7
10328037
J Exp Med. 1999 Jun 21;189(12):1931-8
10377188
J Leukoc Biol. 1999 Sep;66(3):462-70
10496317
Eur J Immunol. 2004 Apr;34(4):981-9
15048708
J Immunol. 2004 May 15;172(10):6281-9
15128817
Trends Immunol. 2004 Jul;25(7):353-9
15207502
J Exp Med. 2004 Jun 21;199(12):1607-18
15197224
J Immunol. 2004 Aug 1;173(3):1934-40
15265927
J Exp Med. 1992 Dec 1;176(6):1693-702
1460426
Infect Immun. 1996 Apr;64(4):1208-14
8606080
J Infect Dis. 1996 Apr;173(4):950-6
8603976
J Exp Med. 1997 Jan 20;185(2):317-28
9016880
Electrophoresis. 1997 Mar-Apr;18(3-4):563-7
9150942
Infect Immun. 1997 Aug;65(8):3386-90
9234802
Nature. 1998 Mar 19;392(6673):245-52
9521319
J Immunol. 1998 Feb 1;160(3):1297-303
9570547
J Exp Med. 2000 May 1;191(9):1525-34
10790427